Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- From: MarilynMann <mannm@xxxxxxxxxxx>
- Date: 24 May 2007 07:16:41 -0700
The Lancet has an editorial on its website discussing the
controversy: http://multimedia.thelancet.com/pdf/rosiglitazone_editorial.pdf.
The unsigned editorial suggests that "the FDA, physicians, and
patients can reasonably await the results of RECORD, a phase III trial
designed specifically to study cardiovascular outcomes."
Asked to comment, Journal Watch Cardiology Editor-in-Chief Harlan M.
Krumholz wrote: "Why would you wait when Avandia has never been shown
to avert events or save lives? And now that there is evidence of
potential harm - and there are alternative meds - it seems to me that
the pressure is on the company to show that it is safe and effective."
Marilyn
.
- Follow-Ups:
- Prev by Date: Re: Please pray for convicted neighbor David Silverman.
- Next by Date: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Previous by thread: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Next by thread: Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- Index(es):
Relevant Pages
|
Loading